Alisertib Market Summary

Key Factors Driving Alisertib Growth

1. Novel Aurora A kinase mechanism with potential to address tumor-cell proliferation: Alisertib is an oral, selective Aurora A kinase (AURKA) inhibitor. Aurora A is involved in mitotic spindle formation and chromosome segregation, and is frequently overexpressed in highly proliferative cancers. This provides a mechanistically differentiated approach from conventional endocrine, chemotherapy and CDK4/6 therapies. Early lymphoma studies demonstrated that alisertib has measurable antitumor activity, supporting continued development across hematologic and solid tumors.

2. Biomarker-driven development could improve response rates: A major current growth driver is Puma's effort to identify patients whose tumors are particularly dependent on the Aurora A pathway. In 2026, Puma reported interim data from ALISCA-Breast1 and ALISCA-Lung1 suggesting greater clinical activity in biomarker-defined populations in which Aurora kinase A appears to play an important role. ALISCA-Breast1 is being expanded during H2 2026 specifically to generate additional data in biomarker-focused subgroups. This precision-medicine strategy could improve the probability of success compared with earlier unselected trials.

3. Significant opportunity in HR-positive/HER2-negative metastatic breast cancer: Puma is evaluating alisertib in combination with endocrine therapy in chemotherapy-naïve, HER2-negative, hormone-receptor-positive metastatic breast cancer through the Phase II ALISCA-Breast1 study. This is a large and clinically important breast-cancer population in which endocrine resistance remains a major problem. The combination strategy could position Aurora A inhibition as an alternative or complementary approach to established cell-cycle therapies if biomarker-selected patients demonstrate meaningful benefit. Puma plans to expand enrollment and present updated data in Q4 2026.

4. Potential opportunity in extensive-stage small-cell lung cancer (ES-SCLC): Alisertib is also being investigated as monotherapy in extensive-stage small-cell lung cancer, a disease characterized by rapid progression and limited treatment options after relapse. The Phase II ALISCA-Lung1 study is expected to expand enrollment during H2 2026, with interim data reported as a key development milestone. Puma's focus on biomarker-defined subgroups may help determine whether AURKA dependence can identify SCLC patients most likely to benefit.

5. Previous clinical evidence demonstrates genuine antitumor activity: Although earlier studies did not establish alisertib as a broad lymphoma treatment, they demonstrated clinically meaningful activity that supports further biomarker-focused investigation. In a Phase II study of relapsed/refractory peripheral T-cell lymphoma, alisertib produced a 30% overall response rate among PTCL patients. In another Phase II study involving aggressive B- and T-cell lymphomas, the overall response rate was 27%, including responses in DLBCL, mantle-cell lymphoma and PTCL. These results establish biological activity even though they also highlight the importance of selecting the right disease and patient population.

Alisertib Recent Developments

In September 2026, Puma Biotechnology, a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. The ALISCA-Lung2 trial is a sequential dose escalation study that will enroll approximately 50 patients with small cell lung cancer who have progressed on or after treatment with platinum-based chemotherapy and immunotherapy.

“Alisertib Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Alisertib for potential indication like Breast cancer, HER2 negative breast cancer, Small cell lung cancer, Squamous cell cancer, and Marginal zone B-cell lymphoma in the 7MM. A detailed picture of Alisertib’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Alisertib for potential indications. The Alisertib market report provides insights about Alisertib’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Alisertib performance, future market assessments inclusive of the Alisertib market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Alisertib sales forecasts, along with factors driving its market.

Alisertib Drug Summary

Alisertib is an investigational, orally bioavailable, highly selective small-molecule inhibitor of Aurora A kinase, originally developed by Takeda and subsequently licensed to Puma Biotechnology for further development. Aurora A is a serine/threonine kinase that plays an essential role in centrosome maturation, mitotic spindle assembly, chromosome alignment, and progression through mitosis; by selectively inhibiting Aurora A, alisertib disrupts spindle formation and chromosome segregation, leading to abnormal mitosis, cell-cycle arrest, and ultimately tumor-cell death. The drug has been administered orally, including as an enteric-coated tablet, and has been evaluated across a range of hematologic malignancies and solid tumors, including peripheral T-cell lymphoma, breast cancer, small-cell lung cancer, non-small-cell lung cancer, and head and neck cancers. Clinical studies have demonstrated pharmacodynamic evidence of Aurora A inhibition and antitumor activity, although treatment has also been associated with adverse effects such as neutropenia, fatigue, nausea, and stomatitis, reflecting its effects on rapidly proliferating cells. Alisertib remains an investigational therapy and is not currently approved for routine clinical use, with its development focused on identifying cancer populations that may derive meaningful benefit from selective Aurora A inhibition. The report provides Alisertib’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Alisertib Market Report

The report provides insights into:

• A comprehensive product overview including the Alisertib MoA, description, dosage and administration, research and development activities in potential indication like Breast cancer, HER2 negative breast cancer, Small cell lung cancer, Squamous cell cancer, and Marginal zone B-cell lymphoma.
• Elaborated details on Alisertib regulatory milestones and other development activities have been provided in Alisertib market report.
• The report also highlights Alisertib‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Alisertib market report also covers the patents information, generic entry and impact on cost cut.
• The Alisertib market report contains current and forecasted Alisertib sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Alisertib market report also features the SWOT analysis with analyst views for Alisertib in potential indications.

Methodology

The Alisertib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Alisertib Analytical Perspective by DelveInsight

• In-depth Alisertib Market Assessment

This Alisertib sales market forecast report provides a detailed market assessment of Alisertib for potential indication like Breast cancer, HER2 negative breast cancer, Small cell lung cancer, Squamous cell cancer, and Marginal zone B-cell lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Alisertib sales data uptil 2034.

• Alisertib Clinical Assessment

The Alisertib market report provides the clinical trials information of Alisertib for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Alisertib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Alisertib Market Potential & Revenue Forecast

• Projected market size for the Alisertib and its key indications
• Estimated Alisertib sales potential (Alisertib peak sales forecasts)
• Alisertib Pricing strategies and reimbursement landscape

Alisertib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Alisertib Market positioning compared to existing treatments
• Alisertib Strengths & weaknesses relative to competitors

Alisertib Regulatory & Commercial Milestones

• Alisertib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Alisertib Clinical Differentiation

• Alisertib Efficacy & safety advantages over existing drugs
• Alisertib Unique selling points

Alisertib Market Report Highlights

• In the coming years, the Alisertib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Alisertib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Alisertib’s dominance.
• Other emerging products for Breast cancer, HER2 negative breast cancer, Small cell lung cancer, Squamous cell cancer, and Marginal zone B-cell lymphoma are expected to give tough market competition to Alisertib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Alisertib in potential indications.
• Analyse Alisertib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Alisertib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Alisertib in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Alisertib? How strong is Alisertib’s clinical and commercial performance?
• What is Alisertib’s clinical trial status in each individual indications such as Breast cancer, HER2 negative breast cancer, Small cell lung cancer, Squamous cell cancer, and Marginal zone B-cell lymphoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Alisertib Manufacturers?
• What are the key designations that have been granted to Alisertib for potential indications? How are they going to impact Alisertib’s penetration in various geographies?
• What is the current and forecasted Alisertib market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Alisertib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Alisertib for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Alisertib? What is the duration of therapy and what are the geographical variations in cost per patient?